Galderma received a Complete Response Letter (CRL) from the FDA for RelabotulinumtoxinA, its neuromodulator candidate positioned as a Botox alternative. A CRL signals the agency cannot approve the application in its current form and requires additional data or manufacturing corrections before resubmission.
Regulatory
Galderma Gets Complete Response Letter on RelabotulinumtoxinA — What Went Wrong
FDA rejects Galderma's Botox rival on first submission; company faces clinical or manufacturing gaps.
CRL signals additional data or manufacturing corrections required before resubmission.
This is a material setback for Galderma's injectables pipeline. While the company has not disclosed the specific deficiencies, CRLs typically stem from inadequate efficacy/safety data, manufacturing process concerns, or labeling issues. Galderma will need to address FDA feedback, conduct additional studies if required, and resubmit—a process that typically adds 12–24 months to market entry. For practices, this extends the competitive window for existing neuromodulators and delays any potential pricing pressure from a new entrant.
Source: original report ↗
Frequently asked questions
What is a Complete Response Letter from the FDA?
A Complete Response Letter (CRL) means the FDA cannot approve a drug application in its current form and requires additional data, studies, or manufacturing corrections before the company can resubmit. It's a formal rejection that typically delays market entry by 12–24 months or longer.
Why did Galderma's RelabotulinumtoxinA get rejected by the FDA?
Galderma has not disclosed the specific deficiencies, but CRLs typically stem from inadequate efficacy or safety data, manufacturing process concerns, or labeling issues. The company will need to address FDA feedback and likely conduct additional clinical studies before resubmission.
How long will it take Galderma to resubmit RelabotulinumtoxinA to the FDA?
Resubmission typically takes 12–24 months after addressing FDA feedback and completing any required additional studies. The exact timeline depends on the nature of the deficiencies and whether new clinical trials are needed.
What does Galderma's CRL mean for med spa pricing on Botox alternatives?
The rejection extends the competitive window for existing neuromodulators like Botox, Dysport, and Xeomin, delaying any potential pricing pressure from a new entrant. Med spas can expect current market dynamics and pricing to remain stable longer.
Is RelabotulinumtoxinA dead or will Galderma try again?
A CRL is not a final rejection—companies routinely address FDA feedback and resubmit. Galderma has not indicated it will abandon the program, but the resubmission process will require significant additional investment and time.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.